2.00

1.48% -0.03

After Hours: 2.0699 0.0699 +3.50%

Eterna Therapeutics Inc (ERNA)

Overview News Price History Financials Discussions Forecast Stock Split

Eterna Therapeutics Inc stock is currently priced at $2.00, with a 24-hour trading volume of 12,620. It has seen a -1.48% decreased in the last 24 hours and a -6.98% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.10 pivot point. If it approaches the $1.96 support level, significant changes may occur.

Previous Close:

$2.03

Open:

$2.02

24h Volume:

12,620

Market Cap:

$10.82M

Revenue:

Net Income/Loss:

$-21.67M

P/E Ratio:

-0.3546

EPS:

-5.64

Net Cash Flow:

$-20.41M

1W Performance:

-1.00%

1M Performance:

-6.98%

6M Performance:

+76.99%

1Y Performance:

-24.81%

1D Range:

$1.94

$2.0699

52W Range:

$0.8401

$2.99

Eterna Therapeutics Inc Stock (ERNA) Company Profile

Name

Eterna Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

212 582 1199

Address

1035 Cambridge Street, Suite 18A, Cambridge

Employee

Twitter

Next Earnings Date

2024-06-14

Latest SEC Filings

ERNA's Discussions on Twitter

Eterna Therapeutics Inc Stock (ERNA) Latest News

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout ... - GlobeNewswire

GlobeNewswire

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout ... - WICZ

WICZ

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

GlobeNewswire Inc.

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout ... - Yahoo Finance

Yahoo Finance

Eterna Therapeutics enhances board with stem cell expert - Investing.com

Investing.com

Eterna Therapeutics enhances board with stem cell expert - Investing.com South Africa

Investing.com South Africa

Eterna Therapeutics Inc Stock (ERNA) Financials Data

Eterna Therapeutics Inc (ERNA) Net Income 2024

ERNA net income (TTM) was -$21.67 million for the quarter ending December 31, 2023, a +11.84% increase year-over-year.

Eterna Therapeutics Inc (ERNA) Cash Flow 2024

ERNA recorded a free cash flow (TTM) of -$20.41 million for the quarter ending December 31, 2023, a +4.07% increase year-over-year.

Eterna Therapeutics Inc (ERNA) Earnings per Share 2024

ERNA earnings per share (TTM) was -$4.08 for the quarter ending December 31, 2023, a +51.37% growth year-over-year.

Eterna Therapeutics Inc. develops messenger RNA (mRNA) cell engineering technologies to repair cellular dysfunction and treat therapeutic indications. It offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. The company also develops therapies and medicines using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.